Children, Only, Refractory Ascites
Conditions
Brief summary
Ascites in liver cirrhosis is explained by increased production of vasoactive substances leading to renal vasoconstriction and salt and water retention. The retained water then accumulates in the peritoneal cavity under the effect of portal hypertension and low albumin. Refractory ascites is defined as ascites that cannot be mobilized or prevented from early recurrence after large-volume paracentesis despite medical therapy and dietary sodium restriction. Midodrine is an α1 receptor agonist that can improve systemic and renal hemodynamics in non-azotemic cirrhotic patients by counteracting mesenteric vasodilatation, which is accentuated in cirrhosis.
Detailed description
Ascites in liver cirrhosis is explained by increased production of vasoactive substances, such as nitric oxide, carbon monoxide, and endocannabinoids, which cause splanchnic vasodilatation, increased blood flow through this area, and a decrease in peripheral vascular resistance and the effective arterial volume with resulting reduction in renal blood flow with subsequent activation of rennin-angiotensin-aldosterone system which in turn leads to renal vasoconstriction and salt and water retention. The retained water then accumulates in the peritoneal cavity under the effect of portal hypertension and low albumin. The International Ascites Club defines refractory ascites as ascites that cannot be mobilized or prevented from early recurrence after large-volume paracentesis despite medical therapy and dietary sodium restriction. There are two varieties of refractory ascites: diuretic-resistant ascites that is unresponsive to the maximal tolerable dose of diuretic therapy and diuretic-intractable ascites when complications such as hepatic encephalopathy, renal dysfunction, or electrolyte abnormalities limit the use of diuretics in the effective therapeutic dose (Cárdenas and Arroyo, 2005) The therapeutic options for refractory ascites are serial therapeutic paracentesis, transjugular intrahepatic portosystemic shunt, peritoneovenous shunt, and liver transplantation. Midodrine is transformed into the active metabolite desglymidodrine, which is an α1 receptor agonist causing an increase in vascular tone and increase in blood pressure without β-adrenergic receptors stimulation so, it can improve systemic and renal hemodynamics in non-azotemic cirrhotic patients by counteracting mesenteric vasodilatation, which is accentuated in cirrhosis. It diffuses poorly across the blood-brain barrier with no central effects. In a study included 600 adult patients with refractory ascites, midodrine was added to diuretic therapy and lead to enhancement of diuresis with the improvement of systemic, renal hemodynamics and short-term survival. Approximately, the only use of midodrine hydrochloride in children was in postural orthostatic tachycardia syndrome (POTS) which showed a good efficacy and safety profile.
Interventions
DRUGMidodrine 2.5 mg tab
Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
Sponsors
National Liver Institute, Egypt
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children aged 7-18 years * Both sexes * Having refractory ascites (not responding to maximal dose of diuretics * Diuretic-induced complications necessitate discontinuation of the drug
Exclusion criteria
* Non-cirrhotic causes of ascites * Intrinsic renal disease ( e.g; polycystic kidney disease) * Active gastrointestinal bleeding or the presence of risky varices * Patients with Portal vein thrombosis and Budd-Chiari * Cardiovascular disease * Systemic hypertension or prehypertension * Hyperthyroidism * Patients with narrow-angle glucoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Side effect no 7 | 3 months | number of patients with skin rash |
| Side effect no 4 | 3 months | number of patients with low heart rate |
| Side effect no 5 | 3 months | number of patients with urine retention |
| Side effect no 6 | 3 months | number of patients with severe itching |
| Side effect no 1 | 3 months | number of patients with Elevated BP: ≥90th percentile to \<95th percentile |
| Side effect no 2 | 3 months | number of patients with Stage 1 HTN: ≥95th percentile to \<95th percentile + 12 mmHg or 130/80 to 139/89 mm Hg (whichever is lower) |
| Side effect no 3 | 3 months | number of patients with Stage 2 HTN: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg (whichever is lower) mmHg or 130/80 to 139/89 mm Hg (whichever is lower) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response | 12 months | absence of ascites by abdominal ultrasound |
| Partial response | 12 months | ascites cannot be mobilized completely but not symptomatic or needs paracentesis |
| non-response | 3 months | no decrease in ascites which still in need for paracentesis after 3 months of duration |
Countries
Egypt
Contacts
Primary ContactBassam Ayoub, MD
Backup ContactMohamed Abdel Hafeez, MD
Outcome results
None listed